[O17] Oral Session 17　Hepatobiliary / Pancreatic Cancer
【E】

[O17-2] A prospective multicenter phase II study of FOLFIRINOX in patients with advanced and recurrent biliary tract cancer

^○Naminatsu Takahara¹, Yousuke Nakai², Toshio Fujisawa³, Takashi Sasaki⁴, Yuji Morine⁵, Kazuo Watanabe⁶, Makoto Ueno⁷, Tatsuya Ioka⁸, Masashi Kanai⁹, Shunsuke Kondo¹⁰, Naohiro Okano¹¹, Hiroyuki Isayama³, Kazuhiko Koike¹ (1.Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 2.Department of Endoscopy and Endoscopic Surgery, Graduate School of Medicine, The University of Tokyo, 3.Department of Gastroenterology, Graduate School of Medicine, The Juntendo University, 4.Division of Hepatobiliary and Pancreatic Medical Oncology, Department of Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 5.Department of Surgery, Tokushima University Graduate School of Biomedical Sciences, 6.Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 7.Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, 8.Oncology Center, Yamaguchi University Hospital, 9.Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, 10.Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital Tokyo, 11.Department of Medical Oncology, Kyorin University, Faculty of Medicine)